Background: Alzheimer disease (AD) is defined neuropathologically by the presence of neurofibrillary tangles and plaques associated with tau and ␤-amyloid protein deposition. The colocalization of microglia and ␤-amyloid plaques has been widely reported in pathological examination of AD and suggests that neuroinflammation may play a role in pathogenesis and/or progression. Because postmortem histopathological analyses are limited to single end-stage assessment, the time course and nature of this relationship are not well understood.
A

DEFINITIVE DIAGNOSIS OF
Alzheimer disease (AD) relies on the demonstration of ␤-amyloid (A␤) plaques and neurofibrillary tangles at autopsy. 1 Microglial activation frequently accompanies A␤ deposition, although the time course of their relationship is unclear. 2 While the exact time course of A␤ deposition in AD has not been elucidated, evidence gained through a postmortem study of Down syndrome (a condition in which A␤ deposition is always present by age 40 years and dementia is common) and an increasing number of reports using the positron emission tomographic (PET) A␤ imaging agent carbon 11 ([ 11 C] )-labeled Pittsburgh Compound B (PiB) suggests that A␤ deposition precedes development of the clinical symptoms of dementia. [3] [4] [5] Compared with control subjects, patients with AD show marked retention of [ 11 C]PiB in areas of brain association cortex known to contain large amounts of A␤ deposits in AD. [6] [7] [8] Levels of [ 11 C]PiB retention comparable to those seen in some subjects with AD have been observed in the cognitively normal elderly population. 4, 5 These and other studies suggest that A␤ deposition precedes significant cognitive decline, although more definitive longitudinal studies in healthy elderly persons are needed to fully characterize the relationship between A␤ deposition and cognitive decline.
The colocalization of activated microglia with A␤-containing neuritic plaques that are characteristic of AD was highlighted by McGeer et al. 9 There is much debate surrounding the central question of whether the role of activated microglia in the pathophysiology of AD is one of neuroprotec-tion or neurotoxicity; this issue has been the subject of many recent reviews. 2, 10 Together, these investigations implicate microglia as at least a participant in the AD process.
Several groups have investigated the utility of selective ligands of the peripheral benzodiazepine receptor (PBR) as surrogate markers for activated brain microglia (as reviewed by Venneti et al 11 ) . Unlike the central benzodiazepine receptor, the PBR is expressed at low levels in the healthy brain. During neuroinflammation associated with AD and a variety of other central nervous system diseases, binding of the PBR radioligand [ 11 C](R)-PK11195 increases in the brain. 11 We have confirmed specific binding of tritium-labeled (R)-PK11195 to simian and human microglia using ex vivo autoradiography in lentiviral encephalitis and AD. 12 Additionally, we have demonstrated increased radiotracer retention in the simian brain consistent with postmortem histopathological confirmation of microglial activation. 13 The goal of our work was to use PET radiotracers to label cerebral A␤ deposits and activated microglia and assess their potential temporal relationship using a crosssectional design. The presence of significant elevations of [
11 C]PiB retention in asymptomatic elderly subjects 4, 5 suggests that significant A␤ aggregation precedes detectable cognitive dysfunction by many years.
14 Therefore, if microglia are involved in the deposition of A␤, one would expect these cells also to be activated years before cognitive dysfunction is detected clinically. One hypothesis is that the brain's immune response to fibrillar A␤ deposits in the form of activation of microglia results in the secretion of a plurality of neurotoxic factors that contribute to synaptic loss and cognitive impairments. The correlation of the time course of microglial activation with the time course of A␤ deposition will help to elucidate the role of neuroinflammation in the pathophysiology of AD.
METHODS
Seventeen subjects (5 control subjects, 6 patients with mild cognitive impairment [MCI] , and 6 patients with mild to moderate AD) were studied with fully dynamic [ 11 C]PiB and [ 11 C](R)-PK11195 PET scans (Table) . This study encompasses all of the subjects who were scanned with both [
11 C]PiB and [ 11 C](R)-PK11195 at our institution. In addition, volumetric magnetic resonance imaging was performed in all of the subjects for anatomical coregistration and volume-of-interest placement. All of the subjects were recruited after diagnostic evaluation at the University of Pittsburgh Alzheimer Disease Research Center in a protocol approved by the University of Pittsburgh Internal Review Board. Each subject received an extensive clinical evaluation. 6, 15 All of the subjects with AD met National Institute of Neurological Disorders and Stroke-Alzheimer's Disease and Related Disorder Association criteria for probable AD and Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) 16 criteria for dementia of the Alzheimer type, 17 and they received the Alzheimer Disease Research Center diagnosis of probable AD at a multidisciplinary consensus conference. Severity for this study was defined by the Mini-Mental State Examination score. 3 Control subjects also underwent the full Alzheimer Disease Research Center evaluation, scored normally on neuropsychiatric evaluations, and received the Alzheimer Disease Research Center consensus diagnosis of healthy control. No exclusion was made for treatment with anticholinesterase drugs as this factor did not affect PiB studies in the initial Swedish cohort of subjects with AD. 4 Informed consent was obtained and the investigator's certification statement was signed (prior to initiating research procedures) by one of the physician investigators (C.A.W.). All of the groups were matched for age (within 2 years), sex, and level of education.
High-specific-activity [ 11 C]PiB was synthesized as described previously. 6 Magnetic resonance-PET image alignment was performed using an automated algorithm for image alignment, reslicing, and region-of-interest (ROI) determination, and indices of radiotracer binding were determined for both [ 11 C]PiB and [ 11 C](R)-PK11195 using previously described methods. As this study did not involve the placement of arterial lines for discrete arterial sampling for input function determination, simplified methods of analysis were applied. For [ . 20 The second was a tissue ratio method whereby the regional radioactivity concentration was summed over the 10-to 60-minute interval and normalized to that determined for subcortical white matter (ROI to subcortical white matter ratio). 21 Due to the potential confounding effects of cerebral atrophy on the study of elderly subjects with PET, all PET data obtained in this project were corrected for partial volume effects using a validated magnetic resonance imaging-based method. 
RESULTS
CEREBRAL ATROPHY CORRECTION
Average regional cerebrospinal fluid correction factors showed statistically significant differences only between the AD and control groups, and then only in the mesial temporal cortex (MTC) (P=.004). Significant differences (PϽ .05) in the degree of cerebral atrophy were observed in the MTC and the sensorimotor cortex when subjects were grouped by [ 11 C]PiB retention status (PiB positive or negative).
[ 11 C]PiB PET IMAGING
All of the subjects were evaluated for [ 11 C]PiB retention status using criteria established through statistical analysis of a larger cohort of subjects (n=62 control subjects) who underwent an essentially identical [ 11 C]PiB imaging study. 22 As applied to our study, a cutoff of 1.65 units in the regional SUV relative to cerebellum over 90 minutes of scanning was used for the frontal cortex and the precuneus region. 7 Any subject with an SUV ratio over 90 minutes that was greater than 1.65 units in either the fron- tal cortex or the precuneus region was classified as PiB positive for the purpose of this analysis.
As a group, the control subjects showed rapid entry and clearance of [ 11 C]PiB in all cortical and subcortical gray matter areas, including cerebellar cortex. In contrast, the patients with AD showed approximately 2-fold greater retention of [ 11 C]PiB than control subjects in areas of the brain known to contain large amounts of A␤ deposits in AD (PϽ.05), such as parietal and frontal cortices as well as the posterior cingulate gyrus and precuneus region (Figure 1C and D) . Subjects with MCI showed patterns of [ 11 C]PiB retention that could be classified as either control-like or AD-like, which resulted in average levels of [ 11 C]PiB retention that were intermediate between control and AD groups. Reclassification of subjects into PiB-positive and PiB-negative groups based on the aforementioned criteria for determining [ 11 C]PiB positivity showed a very clear delineation between groups expected to have significant A␤ pathological findings and those without (P Ͻ.01) (Figure 2) . In general, the observed pattern of [ 11 C]PiB retention was consistent with the pattern of A␤ plaque deposition described in postmortem studies of AD brain 23, 24 as well as other published reports using [ 11 C]PiB to image brain ␤-amyloidosis in AD. [6] [7] [8] In this study, 12 of 17 subjects studied were classified as PiB positive (6 of 6 patients with AD, 4 of 6 patients with MCI, and 2 of 5 control subjects). Most PiB-positive subjects showed evidence of increased [
11 C]PiB retention in all brain areas, but 2 of the 12 PiB-positive subjects showed more focal [
11 C]PiB retention ( Figure 2B ). (Figure 3) . The BP estimates of regional [ 11 C](R)-PK11195 retention derived using the simplified reference tissue method varied with a mean near 0, suggesting that voxelwise BP estimates were most likely attributable to statistical noise and not signal from activated microglia (data not shown). The use of a late-scan tissue ratio (ROI to subcortical white matter reference region ratio) without application of the cerebral atrophy correction showed slightly lower ratios in patients with AD relative to both control and MCI groups, suggesting a trend toward decreased binding of [ 11 C](R)-PK11195 in PiB-positive subjects compared with PiB-negative subjects (Figure 4) . However, these differences did not reach the level of significance and only approached trend-level differences in the MTC (P=.14). Correction of the ROI to subcortical white matter ratio for atrophy negated any apparent differences in the re- 
COMMENT
The PBR ligand PK11195 has undergone development as an agent for assessing macrophage and microglial activation in neurological disease for nearly 2 decades. 11, [25] [26] [27] [28] Six years after the initial report by Groom and colleagues, Cagnin et al 30 reported a similar study using the more active R-enantiomer of [ 11 C]PK11195, comparing 15 control subjects, 8 patients with AD (5 mild and 3 moderate), and 1 patient with MCI. They observed small BP increases bilaterally in the fusiform, inferior, and middle temporal gyri and in the left parahippocampal gyrus, amygdala, and posterior cingulate gyrus of patients with AD. Further, they noted an age-related increase in [ 11 C](R)-PK11195 BP in the thalamus that was not specific to AD. Versijpt et al 31 described the utility of a radioiodinated analog of PK11195 for single-photon emission computed tomographic imaging, [
123 I]iodo-PK11195, which showed increased uptake in nearly all neocortical regions of 10 patients with AD compared with 9 control subjects, but this only achieved significance in the frontal and right MTC regions, which are notably free of [ 11 C] plaques in mild to moderate AD. Other neurodegenerative diseases have also been assessed with [ 11 C](R)-PK11195 (eg, Huntington disease and multiple system atrophy), but there was no simple correspondence between clinically involved regions and [
11 C](R)-PK11195 binding. 32, 33 The observed distribution of [ 11 C]PiB in patients with mild to moderate AD in this study is consistent with prior reports showing the highest [
11 C]PiB retention in the posterior cingulate gyrus, parietal cortex, and frontal cortex but relatively low binding in the MTC regions such as the amygdala and hippocampus. 4, [6] [7] [8] This characteristic distribution of in vivo [
11 C]PiB retention reflects the known distribution of A␤ plaques in AD, which are most abundant in the neocortical regions but relatively absent from the MTC regions. 24 Interestingly, the prior literature suggests an elevation of [
11 C](R)-PK11195 retention in the MTC regions in AD, 30, 31 an area characterized by low densities of neuritic plaques but high densities of neurofibrillary tangles, 24 suggesting an incongruity between microglial activation as assessed by [ 11 C](R)-PK11195 retention and the known pattern of A␤ deposition. This incongruity may have several important implications. The first is the possibility that microglial activation in AD is not a specific indicator of A␤ plaque load. The second is that the previously observed regional increases in binding of tington disease study 33 suggested that [ 11 C](R)-PK11195 detected microglial activation in 11 presymptomatic disease gene carriers. That study showed low but significantly increased regional [ 11 C](R)-PK11195 BP values in Huntington disease gene carriers relative to healthy control subjects. Our similarly sized study of AD did not detect significant differences in [ 11 C](R)-PK11195 BP between patients with AD and control subjects, but after atrophy correction, it showed a trend toward decreased binding in AD.
Considering the postmortem literature showing a spatial relationship between A␤ pathological burden and microglial activation, the failure of this study to detect increases in microglial activation using [ 11 C](R)-PK11195 in subjects where considerable A␤ pathological burden is presumably manifested (PiB-positive subjects) can be interpreted in several ways. The first is that A␤ deposition precedes microglial activation and is itself the principal substrate of neuronal degeneration and cognitive impairment in AD. In this interpretation, microglial activation is not involved early in the AD disease process but becomes more of a feature of the disease many years later in its terminal stages. This would seem to argue that microglial activation is more of an inert product than a significant participant of the neurodegenerative processes involved in AD. A second interpretation is that microglial activation is a feature of early AD, perhaps even presymptomatic AD, but that [ The advent of anti-A␤ therapies clearly demonstrates a pressing need for technology that would allow for noninvasive in vivo quantitation of A␤ and microglia in the human brain. One theory of how anti-A␤ therapies clear A␤ deposition is through A␤ opsonization and microglialmediated destruction. The small number of autopsy reports from the AN 1792 A␤ immunization study showed decreased A␤ load and increased microglial activation, 34, 35 suggesting that the increased microglial activation attributable to A␤ immunization resulted in the significant clearance of brain amyloid deposits. However, because we have no measure of pretreatment amyloid load, it is not possible to definitively document the therapeutic effect in humans. 36 Antiamyloid therapies such as passive immunization with anti-A␤ antibodies are promising avenues in the treatment and prevention of AD. The ability to quantify A␤ load and microglial activation prior to treatment and then follow the effects of treatment is critical to the efficient development of this therapy. If these therapies become an effective treatment for AD, it also will be critical to have a means of evaluating clinical success, particularly in mildly impaired subjects with few clinical symptoms to follow. Finally, the ability to follow the natural history of A␤ deposition and its relationship to microglial activation beginning in the presymptomatic stage should yield important pathophysiological insights regarding the accuracy of the amyloid cascade hypothesis of AD. To accomplish this, a marker demonstrated to be both a reliable and robust indicator of microglial activation in vivo will be essential.
Accepted for Publication: July 9, 2008. 
